SI-BONE, Inc.

133 articles with SI-BONE, Inc.

• SI-BONE, Inc. Reports Third Quarter 2021 Financial Results and Updates 2021 Financial Guidance

  11/8/2021

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended September 30, 2021.

• SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021

  10/18/2021

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2021 after market close on Monday, November 8, 2021.

• SI-BONE, Inc. Announces UnitedHealthcare Adopts Exclusive iFuse Only Coverage for Minimally Invasive SI Joint Fusion

  10/11/2021

  SI-BONE, Inc. announced that UnitedHealthcare has changed its minimally invasive SI joint fusion policy from covering all devices to exclusively covering SI-BONE’s triangular iFuse Implants, effective October 1, 2021.

• SI-BONE to Participate in Upcoming Conferences

  8/23/2021

  SI-BONE, Inc.today announced that it will be participating in the following upcoming investor conferences: 19 th Annual Morgan Stanley Global Healthcare Conference Fireside Chat on Tuesday, September 14, 2021, 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time.

• SI-BONE, Inc. Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem

  8/2/2021

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended June 30, 2021.

• SI-BONE, Inc. Announces Anthem, Inc. Adopts Coverage Guidelines for Sacroiliac Joint Fusion Exclusive to the Triangular iFuse Implant System® for Its More Than 40 Million Members

  8/2/2021

  SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that Anthem, Inc. will cover minimally invasive SI joint fusion exclusively when performed with the iFuse system of triangular titanium implants.

• SI-BONE to Present at the Canaccord Genuity 41st Annual Growth Conference

  7/29/2021

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that the company will be participating in the upcoming Canaccord Genuity 41st Annual Growth Conference.

• SI-BONE To Report Second Quarter 2021 Financial Results on August 2, 2021

  7/20/2021

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2021 after market close on Monday, August 2, 2021.

• SI-BONE, Inc. Announces Centene Establishes Positive Coverage for MIS SI Joint Fusion including the Triangular iFuse Implant System

  7/14/2021

  SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that Centene Corporation has established a positive coverage policy for minimally invasive SI joint fusion.

• SI-BONE, Inc. Announces Publication of iFuse-3D Implant Clinical Study Results Showing Accelerated Fusion, Immediate and Sustained Clinical Improvements and Reduction in Opioid Use

  7/7/2021

  SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy announced the publication of 2-year results from SALLY 1, a prospective multicenter clinical trial of the iFuse-3D™ Implant System.

• SI-BONE, Inc. Announces the Introduction of the SI-BONE SImulator™ Powered by Medability for iFuse Surgeon Training and Education

  7/2/2021

  SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the worldwide launch of the SI-BONE SImulator™.

• French National Healthcare System Adopts Exclusive Reimbursement Policy for SI-BONE, Inc.’s iFuse-3D Implant System™Exclusive Coverage Takes Effect June 1, 2021, and Extends for 5 Years

  6/15/2021

  SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy announced that the French Health Ministry has granted national reimbursement for the iFuse-3D Implant System™.

• SI-BONE to Present at the 2021 JMP Securities Life Sciences Conference

  6/8/2021

  SI-BONE, Inc. (Nasdaq: SIBN),  today announced that the company will be participating in the upcoming 2021 JMP Securities Life Sciences Conference.

• SI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidance

  5/3/2021

  SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2021.

• SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors

  4/19/2021

  SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company’s Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021.

• SI-BONE To Report First Quarter 2021 Financial Results on May 3, 2021

  4/15/2021

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2021 after market close on Monday, May 3, 2021.

• SI-BONE, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Issues 2021 Financial Guidance

  3/8/2021

  SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter and full year ended December 31, 2020.

• SI-BONE To Report Fourth Quarter and Full Year 2020 Financial Results on March 8, 2021

  2/9/2021

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Monday, March 8, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

• SI-BONE Announces Senior Leadership Changes and Record Quarterly Revenue

  1/7/2021

  SI-BONE, Inc., a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, announced its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors.

• SI-BONE to Present at the 23rd Annual Needham Growth Conference and the 39th Annual J.P. Morgan Healthcare Conference

  12/17/2020

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 23 rd Annual Needham Growth Conference and the 39 th Annual J.P. Morgan Healthcare Conference. For the Needham Growth Conference, SI-BONE’s management is scheduled for a Fireside Chat on Monday, January 11, 2021 at 2:45 p.m. Eastern